Nektar Therapeutics (NKTR) Stock Grade

About Nektar Therapeutics's fundamentals

Nektar Therapeutics is a biotechnology company with a market capitalization of $1.7 billion that reported a significant net loss in its latest annual statement, resulting in a negative net margin of -297.1%. The company experienced substantial revenue decline, with year-over-year revenue falling 43.9%, indicating a contraction in its commercial performance. As a loss-making biotechnology firm, the company does not currently pay dividends and lacks meaningful profitability metrics such as a positive P/E ratio or return on equity.